EP0190018A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of transforming growth factor to promote wound healing and composition therefor
Assignee: Oncogen LP
•
Filing: 1986-01-24
•
Granted: —
•
Expires: 2006-01-24
Abstract
Abstract Compositions including a polypeptide having the amino acid sequence of transforming growth-factor-α are for topical application to wounds, particularly corneal stromal wounds.
Inventors
- 👤 George J. Todaro
- 👤 Gregory L. Schultz
- 👤 Richard Eiferman
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 12:14
CPC Classifications
A; A61; A61L; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0047; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A61K; A61K38/00
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
26 words
A composition for the treatment of epithelial and stromal wounds, said composition comprising: transforming growth factor-α (TGF-d) substantially free from naturally-occurring contaminants in a physiologically-acceptable carrier.
Claim 2
Dependent Claim
26 words
A composition for the treatment of epithelial and stromal wounds, said composition comprising: transforming growth factor-α (TGF-d) substantially free from naturally-occurring contaminants in a physiologically-acceptable carrier.
Claim 3
Dependent Claim
30 words
A composition according to claim 1 wherein the carrier is an ointment, or a sterile saline solution and the TGF-α is at a concentration from 1 pg/ml to 10 mg/ml.
Claim 4
Dependent Claim
13 words
A composition according to claim 1 or 2, wherein the TGF-α is rTGF-α.
Claim 5
Dependent Claim
16 words
A composition according to any of the preceeding claims, wherein the TGF-α is synthesized in vitro.
Claim 6
Dependent Claim
13 words
A composition according to claim 4, wherein the TGF-0(is prepared by solid-phase synthesis.
Claim 7
Dependent Claim
11 words
TGF-α for use in the promotion of the healing of wounds.
Claim 8
Dependent Claim
11 words
TGF-α for use in the promotion of the healing of wounds.
Claim 9
Dependent Claim
14 words
TGF-d for use in the promotion of the healing of wounds in the cornea.
Claim 10
Dependent Claim
14 words
TGF-d for use in the promotion of the healing of wounds in the cornea.
Claim 11
Independent Claim
33 words
A method for treating epithelial and stromal wounds to promote healing thereof, said method comprising applying transforming growth factor-α (TGF-α) to the region of the wound in an amount effective to promote healing.
Claim 12
Independent Claim
33 words
A method for treating epithelial and stromal wounds to promote healing thereof, said method comprising applying transforming growth factor-α (TGF-α) to the region of the wound in an amount effective to promote healing.
Claim 13
Dependent Claim
18 words
A method according to claim 8, wherein the TGF-α is applied in the region of a corneal wound.
Claim 14
Dependent Claim
19 words
A method according to claim 9, wherein the TGF-α is applied in the region of a corneal stromal wound.
Claim 15
Independent Claim
28 words
A method of preparing a composition for treating epithelial and stromal wounds to promote healing thereof, said method comprising admixing transforming growth factor-d (TGF-α) with a physiologically-acceptable carrier.
Claim 16
Independent Claim
28 words
A method of preparing a composition for treating epithelial and stromal wounds to promote healing thereof, said method comprising admixing transforming growth factor-d (TGF-α) with a physiologically-acceptable carrier.
Claim 17
Dependent Claim
28 words
A method according to claim 1, wherein the TGF-α is admixed in the physiologically acceptable carrier at a concentration in the range from 1 pg/ml to 10 mg/ml.
Claim 18
Dependent Claim
24 words
A method according to claim 1 or claim 2, including synthesizing the TGF-α in vitro and to have the amino acid sequence of rTGF-α.
Claim 19
Dependent Claim
14 words
A method according to claim 3 wherein the TGF-d is prepared by solid-phase synthesis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.